Gamble Jones Investment Counsel trimmed its holdings in shares of Pfizer Inc. (NYSE:PFE) by 3.5% in the third quarter, according to the company in its most recent filing with the SEC. The institutional investor owned 304,094 shares of the biopharmaceutical company’s stock after selling 10,871 shares during the quarter. Pfizer accounts for 1.2% of Gamble Jones Investment Counsel’s holdings, making the stock its 17th biggest position. Gamble Jones Investment Counsel’s holdings in Pfizer were worth $13,401,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also bought and sold shares of PFE. Stone Ridge Asset Management LLC grew its stake in shares of Pfizer by 44.1% during the 3rd quarter. Stone Ridge Asset Management LLC now owns 332,474 shares of the biopharmaceutical company’s stock worth $14,652,000 after acquiring an additional 101,691 shares in the last quarter. Wellington Shields & Co. LLC grew its stake in shares of Pfizer by 3.2% during the 3rd quarter. Wellington Shields & Co. LLC now owns 55,468 shares of the biopharmaceutical company’s stock worth $2,444,000 after acquiring an additional 1,701 shares in the last quarter. Gryphon Financial Partners LLC grew its stake in shares of Pfizer by 64.2% during the 3rd quarter. Gryphon Financial Partners LLC now owns 20,552 shares of the biopharmaceutical company’s stock worth $906,000 after acquiring an additional 8,032 shares in the last quarter. O Shaughnessy Asset Management LLC grew its stake in shares of Pfizer by 381.9% during the 3rd quarter. O Shaughnessy Asset Management LLC now owns 45,199 shares of the biopharmaceutical company’s stock worth $1,987,000 after acquiring an additional 35,820 shares in the last quarter. Finally, Quadrant Private Wealth Management LLC grew its stake in shares of Pfizer by 9.2% during the 3rd quarter. Quadrant Private Wealth Management LLC now owns 28,346 shares of the biopharmaceutical company’s stock worth $1,249,000 after acquiring an additional 2,396 shares in the last quarter. 69.06% of the stock is owned by institutional investors and hedge funds.

In other Pfizer news, EVP Douglas M. Lankler sold 38,800 shares of the firm’s stock in a transaction on Wednesday, January 30th. The stock was sold at an average price of $41.19, for a total transaction of $1,598,172.00. Following the completion of the sale, the executive vice president now owns 83,592 shares of the company’s stock, valued at approximately $3,443,154.48. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Douglas M. Lankler sold 5,000 shares of the firm’s stock in a transaction on Friday, February 1st. The shares were sold at an average price of $42.75, for a total value of $213,750.00. Following the sale, the executive vice president now directly owns 83,592 shares of the company’s stock, valued at approximately $3,573,558. The disclosure for this sale can be found here. 0.06% of the stock is currently owned by company insiders.

Several equities analysts have recently weighed in on the stock. Zacks Investment Research cut shares of Pfizer from a “hold” rating to a “sell” rating in a research note on Friday, January 25th. ValuEngine cut shares of Pfizer from a “buy” rating to a “hold” rating in a research note on Thursday, January 24th. Credit Suisse Group set a $42.00 price target on shares of Pfizer and gave the stock a “hold” rating in a research note on Monday, November 26th. Societe Generale set a $43.00 price target on shares of Pfizer and gave the stock a “hold” rating in a research note on Thursday, November 1st. Finally, Cantor Fitzgerald reaffirmed a “buy” rating and set a $53.00 price target on shares of Pfizer in a research note on Monday, November 19th. Three analysts have rated the stock with a sell rating, thirteen have issued a hold rating and seven have given a buy rating to the stock. The company currently has a consensus rating of “Hold” and a consensus target price of $44.68.

NYSE:PFE opened at $42.23 on Friday. Pfizer Inc. has a 1-year low of $33.20 and a 1-year high of $46.47. The company has a debt-to-equity ratio of 0.47, a current ratio of 1.43 and a quick ratio of 1.15. The firm has a market capitalization of $248.23 billion, a P/E ratio of 14.08, a PEG ratio of 2.42 and a beta of 0.77.

Pfizer (NYSE:PFE) last released its earnings results on Tuesday, January 29th. The biopharmaceutical company reported $0.64 earnings per share for the quarter, beating the consensus estimate of $0.63 by $0.01. Pfizer had a net margin of 20.79% and a return on equity of 25.38%. The business had revenue of $13.98 billion during the quarter, compared to analysts’ expectations of $13.92 billion. During the same period last year, the business earned $0.62 earnings per share. The firm’s revenue was up 2.0% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.86 EPS for the current year.

Pfizer announced that its Board of Directors has initiated a stock repurchase plan on Friday, December 14th that allows the company to buyback $10.00 billion in shares. This buyback authorization allows the biopharmaceutical company to buy up to 3.8% of its shares through open market purchases. Shares buyback plans are generally a sign that the company’s board of directors believes its stock is undervalued.

The company also recently announced a quarterly dividend, which will be paid on Friday, March 1st. Investors of record on Friday, February 1st will be paid a $0.36 dividend. The ex-dividend date of this dividend is Thursday, January 31st. This is a boost from Pfizer’s previous quarterly dividend of $0.34. This represents a $1.44 annualized dividend and a dividend yield of 3.41%. Pfizer’s dividend payout ratio (DPR) is currently 48.00%.

ILLEGAL ACTIVITY NOTICE: “Gamble Jones Investment Counsel Lowers Position in Pfizer Inc. (PFE)” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are accessing this story on another site, it was stolen and republished in violation of U.S. and international trademark & copyright law. The original version of this story can be viewed at https://www.thecerbatgem.com/2019/02/09/gamble-jones-investment-counsel-lowers-position-in-pfizer-inc-pfe.html.

Pfizer Company Profile

Pfizer Inc discovers, develops, manufactures, and sells healthcare products worldwide. It operates in two segments, Pfizer Innovative Health (IH) and Pfizer Essential Health (EH). The IH segment focuses on the development and commercialization of medicines and vaccines, and consumer healthcare products in various therapeutic areas, including internal medicine, vaccines, oncology, inflammation and immunology, and rare diseases, as well as consumer healthcare, such as over-the-counter brands comprising dietary supplements, pain management, gastrointestinal, and respiratory and personal care.

Read More: Is a Roth IRA right for you?

Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer Inc. (NYSE:PFE).

Institutional Ownership by Quarter for Pfizer (NYSE:PFE)

Receive News & Ratings for Pfizer Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer and related companies with MarketBeat.com's FREE daily email newsletter.